Biologics That Can Expect a Biosimilar in the Near Future

The clock is ticking for originator biologics as they hold on to the last few years or months of their patent. Multiple patents are expected to expire on biologic products by 2020 and the development of some biosimilars is already underway.

The Amgen 2015 Trends in Biosimilars Report reviewed leading biologics in the United States that anticipate patent expiration in the upcoming years including Humira^®, Remicade^®, and Levemir^®. See Table 1 for biologic and expected patent expiration.

_________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Adopting Biosimilars in the US: Overcoming the Obstacles
Some Specialists Leery of Prescribing Biosimilars

_________________________________________________________________________________________________________________________________________________________

According to the Amgen 2015 Trends in Biosimilars Report, 5 biologics have biosimilars in development. See Table 2. The therapeutic areas these biologics cover include certain inflammatory diseases and oncology.

Whether biosimilars are as cost saving as some expect will depend upon multiple factors including physician’s knowledge of biosimilars, patient willingness to try a biosimilar, etc.—Melissa D. Cooper

Reference

2015 Trends in Biosimilars Report. Thousand Oaks, CA: Amgen. https://www.amgenbiosimilars.com/~/media/amgen/full/www-amgenbiosimilars-com/downloads/2015_trends_in_biosimilars_report.ashx?la=en. Accessed August 28, 2015.